Jump to contents

Researcher Information

last modified：2024/03/31

Professor　TAKAMATSU, Hiroyuki

Faculty, Affiliation

Faculty of Transdisciplinary Sciences, Institute of Philosophy in Interdisciplinary Sciences

College and School Educational Field


School of Entrepreneurial and Innovation Studies, College of Transdisciplinary Sciences for Innovation

Laboratory

Hematology & Respirology

Academic Background

【Academic background(Doctoral/Master's Degree)】
Kanazawa University　Doctor　Completed
【Academic background(Bachelor's Degree)】
Kanazawa University
【Degree】
MD, PhD

Career

Year & Month of Birth

Academic Society








European Hematology Association
The American Society of Hematology





The Japanese Society of Hematology



Award



Specialities

Hematology

Speciality Keywords

Hematology, Biotechonology

Research Themes

Books

Papers

  • 　A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. 　Hiroyuki Takamatsu (Corresponding author), Rachel K Wee, Yoshitaka Zaimoku, Ryoichi Murata, Jianbiao Zheng, Martin Moorhead, Victoria E. H. Carlton, Katherine A. Kong, Naoki Takezako, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Kosei Matsue, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Morio Matsumoto, Takashi Yoshida, Malek Faham and Shinji Nakao. 　Br J Haematol　2017/09/01
  • 　Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.　Hiroyuki Takamatsu 　Journal of Clinical Medicine　6　10　91　2017/06/01
  • 　Identification of an HLA class I allele closely involved in the auto-antigen presentation in acquired aplastic anemia.　Zaimoku Y, Takamatsu H, Hosomichi K, Ozawa T, Nakagawa N, Imi T, Maruyama H, Katagiri T, Kishi H, Tajima A, Muraguchi A, Kashiwase K, Nakao S.　Blood　2017
  • 　Successful hyperbaric oxygen therapy for refractory BK virus-associated hemorrhagic cystitis after cord blood transplantation　Hosokawa K, Yamazaki H, Nakamura T, Yoroidaka T, Imi T, Shima Y, Ohata K, Takamatsu H, Kotani T, Kondo Y, Takami A, Nakao S　Transpl Infect Dis　2014
  • 　造血幹細胞移植後のガンマグロブリン予防投与（0.1g/kg/週）の有効性の検討：単一施設での後方視的解析　高松博幸、材木義隆、丸山裕之、細川晃平、斉藤千鶴、清木ゆう、大畑欣也、望月果奈子、小谷岳春、近藤恭夫、山崎宏人、高見昭良、中尾眞二　日本輸血・細胞治療学会誌　59　1　43-47　2013

show all

  • 　Phase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosisPhase 1 study of bortezomib in combination with melphalan and dexamethasone in Japanese patients with relapsed AL amyloidosis　Chihiro Shimazaki, Shin‑ichi Fuchida, Kenshi Suzuki, Tadao Ishida, Hirokazu Imai, Morio Sawamura, Hiroyuki Takamatsu, Masahiro Abe, Toshihiro Miyamoto, Hiroyuki Hata, Masahito Yamada, Yukio Ando　Int J Hematol　103　79-85　2016
  • 　Changing trends in prognostic factors for patients with multiple myeloma after autologous stem cell transplantation during the immunomodulator drug/proteasome inhibitor era　Hiroyuki Takamatsu, Sumihisa Honda, Toshihiro Miyamoto, Kenji Yokoyama, Shotaro Hagiwara, Toshiro Ito, Naoto Tomita, Shinsuke Iida, Toshihiro Iwasaki, Hisashi Sakamaki, Ritsuro Suzuki, Kazutaka Sunami　Cancer Science　106　2　179-185　2015
  • 　Cord Blood Transplantation for Multiple Myeloma: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplantation　Kawamura K, Takamatsu H, Ikeda T, Komatsu T, Aotsuka N, Amano I, Yamamoto G, Watanabe K, Ohno Y, Matsue K, Kouzai Y, Tsukada N, Ishiyama K, Anzai N, Kato K, Suzuki R, Sunami K, Kanda Y　Biol Blood Marrow Transplant　21　7　1291　2015
  • 　 t(14;16)-positive multiple myeloma shows negativity for CD56 expression and unfavorable outcome even in the era of novel drugs　Shinsuke Iida, Tomoko Narita, Atsushi Inagaki, Tsutomu Kobayashi, Yoshiaki　Kuroda, Toshihiro Fukushima, Masahiko Nezu, Shinichi Fuchida, Hirotaka Sakai, Naohiro Sekiguchi, Isamu Sugiura, Yoshinobu Maeda, Hiroyuki Takamatsu, Norifumi Tsukamoto, Dai Maruyama, Yasushi Kubota, Minoru Kojima, Kazutaka Sunami, Takaaki Ono, Masaki Ri, and Kensei Tobinai　Blood Cancer Journal　27　5　e285　2015
  • 　Cyclosporine restores hematopoietic function by compensating for decreased Tregs in patients with pure red cell aplasia and acquired aplastic anemia　Dao AT, Yamazaki H, Takamatsu H, Sugimori C, Katagiri T, Maruyama H, Zaimoku Y, Maruyama K, Ly TQ, Espinoza L, Nakao S　Ann Hematol　95　5　771-81　2016
  • 　骨髄腫患者の経過観察中に必要な検査　52　12　2156-2160　2015
  • 　Epstein–Barr virus-associated leukemic lymphoma after allogeneic stem cell transplantation　Hiroyuki Takamatsu　Journal of Clinical Virology　80　82-86　2016
  • 　Role of Moesin in Murine Hematopoiesis　Takamatsu, Hiroyuki;Espinoza, Luis J.;Nakao, Shinji　BLOOD　118　21　589-590　2011
  • 　Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response　Takamatsu, Hiroyuki;Yagasaki, Hiroshi;Takahashi, Yoshiyuki;Hama, Asahito;Saikawa, Yutaka;Yachie, Akihiro;Koizumi, Shoichi;Kojima, Seiji;Nakao, Shinji　EUROPEAN JOURNAL OF HAEMATOLOGY　86　6　541-545　2011
  • 　Post-transplantation consolidation and maintenance therapy with lenalidomide for Japanese patients with multiple myeloma　Takamatsu, Hiroyuki; Munemoto, Saori; Murata, Ryoichi; Terasaki, Yasushi; Nakajima, Kenichi; Nakao, Shinji　Anticancer Research　33　12　5681-5685　2013/12/01　
  • 　Detection of minimal residual disease in patients with multiple myeloma using clonotype-specific PCR primers designed from DNA extracted from archival bone marrow slides　Takamatsu, Hiroyuki; Ogawa, Yoshiyasu; Kobayashi, Noriko; Obata, Kazue; Narisawa, Tadashi; Nakayama, Kouji; Munemoto, Saori; Aoki, Go; Ohata, Kinya; Kumano, Yoshihisa; Ozaki, Jun; Murata, Ryoichi; Kondo, Yukio; Terasaki, Yasushi; Kurokawa, Toshiro; Miyamoto, Toshihiro; Shimizu, Naomi; Fukushima, Toshihiro; Yoshida, Akira; Ueda, Takanori; Yoshida, Takashi; Nakao, Shinji　Experimental Hematology　41　10　894-902　2013/10/01　
  • 　Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem cell transplantation.　Hiroyuki Takamatsu (Corresponding author), Naoki Takezako, Jianbiao Zheng, Martin Moorhead, Victoria E. H. Carlton, Katherine A. Kong, Ryoichi Murata, Shigeki Ito, Toshihiro Miyamoto, Kenji Yokoyama, Kosei Matsue, Tsutomu Sato, Toshiro Kurokawa, Hideo Yagi, Yasushi Terasaki, Kinya Ohata, Morio Matsumoto, Takashi Yoshida, Malek Faham and Shinji Nakao. 　Ann Oncol　28　2503-2510　2017
  • 　Detection of Minimal Residual Disease in Patients with Multiple Myeloma by PCR-Based IGH Gene Clonality Analysis Using DNA Extracted From Archival Bone Marrow Slides　Takamatsu, Hiroyuki;Ogawa, Yoshiyasu;Kobayashi, Noriko;Obata, Kazue;Narisawa, Tadashi;Nakayama, Kouji;Nakao, Shinji　BLOOD　118　21　820-821　2011
  • 　Thymoglobuline Is As Effective As Lymphoglobuline in Japanese Patients with Aplastic Anemia Possessing Increased Glycosylphosphatidylinositol-Anchored Protein (GPI-AP) Deficient Cells　Yamazaki, Hirohito;Saito, Chizuru;Sugimori, Naomi;Hosokawa, Kohei;Kiyu, Yu;Mochizuki, Kanako;Takamatsu, Hiroyuki;Nakao, Shinji　BLOOD　118　21　590-590　2011
  • 　Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016-2021)　Hirohiko Shibayama 1 2, Mitsuhiro Itagaki 3, Hiroshi Handa 4, Akihiro Yokoyama 5, Akio Saito 6, Satoru Kosugi 7, Shuichi Ota 8, Makoto Yoshimitsu 9, Yasuhiro Tanaka 10, Shingo Kurahashi 11, Shin-Ichi Fuchida 12, Masaki Iino 13, Takayuki Shimizu 14, Yukiyoshi Moriuchi 15, Kohtaro Toyama 16, Kinuko Mitani 17, Yutaka Tsukune 18, Akiko Kada 19, Hideto Tamura 20, Masahiro Abe 21, Hiromi Iwasaki 22, Junya Kuroda 23, Hiroyuki Takamatsu 24, Kazutaka Sunami 25, Masahiro Kizaki 26, Tadao Ishida 27, Toshiki Saito 19, Itaru Matsumura 28, Koichi Akashi 29, Shinsuke Iida 30　Int J Hematol . 　2024/03/29
  • 　3D CNN-based Deep Learning Model-based Explanatory Prognostication in Patients with Multiple Myeloma using Whole-body MRI　Kento Morita 1, Shigehiro Karashima 2, Toshiki Terao 3 4, Kotaro Yoshida 5, Takeshi Yamashita 6, Takeshi Yoroidaka 7 8, Mikoto Tanabe 7, Tatsuya Imi 8, Yoshitaka Zaimoku 8, Akiyo Yoshida 8, Hiroyuki Maruyama 8, Noriko Iwaki 8, Go Aoki 8, Takeharu Kotani 7, Ryoichi Murata 6, Toshihiro Miyamoto 8, Youichi Machida 9, Kosei Matsue 3, Hidetaka Nambo 10, Hiroyuki Takamatsu 11 12　J Med Syst . 　48　1　30　2024/03/08
  • 　A prospective, multicenter, observational study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma in Japan　Yuichi Horigome 1, Masaki Iino 2, Yoriko Harazaki 3, Takahiro Kobayashi 4, Hiroshi Handa 5, Yasushi Hiramatsu 6, Taiga Kuroi 7, Kazuki Tanimoto 8, Kosei Matsue 9, Masahiro Abe 10, Tadao Ishida 11, Shigeki Ito 12, Hiromi Iwasaki 13, Junya Kuroda 14, Hirohiko Shibayama 15, Kazutaka Sunami 16, Hiroyuki Takamatsu 17, Hideto Tamura 18, Toshiaki Hayashi 19, Kiwamu Akagi 20, Takahiro Maeda 21, Takahiro Yoshida 22, Ikuo Mori 22, Tomohiro Shinozaki 23, Shinsuke Iida 24　Ann Hematol .　103　2　475　2024/02/01
  • 　ctDNA improves prognostic prediction in relapsed/refractory MM receiving ixazomib, lenalidomide, and dexamethasone　Yasunori Kogure 1, Hiroshi Handa 2, Yuta Ito 3, Masaki Ri 4, Yuichi Horigome 5, Masaki Iino 6, Yoriko Harazaki 7, Takahiro Kobayashi 8, Masahiro Abe 9, Tadao Ishida 10, Shigeki Ito 11, Hiromi Iwasaki 12, Junya Kuroda 13, Hirohiko Shibayama 14, Kazutaka Sunami 15, Hiroyuki Takamatsu 16, Hideto Tamura 17, Toshiaki Hayashi 18, Kiwamu Akagi 19, Tomohiro Shinozaki 20, Takahiro Yoshida 21, Ikuo Mori 21, Shinsuke Iida 22, Takahiro Maeda 23, Keisuke Kataoka 24　Blood　2024/03/01
  • 　HLA Class I Allele Loss and Bone Marrow Transplantation Outcomes in Immune Aplastic Anemia　Yoshitaka Zaimoku 1, Takamasa Katagiri 2, Noriharu Nakagawa 3, Tatsuya Imi 3, Hiroyuki Maruyama 3, Hiroyuki Takamatsu 4, Ken Ishiyama 3, Hirohito Yamazaki 5, Toshihiro Miyamoto 3, Shinji Nakao 6　Transplant Cell Ther .　30　3　281　2024/03/01
  • 　Minor GPI(-) granulocyte populations in aplastic anemia and healthy individuals derived from a few PIGA-mutated hematopoietic stem progenitor cells　Hiroki Mizumaki 1, Dung Cao Tran 1, Kohei Hosokawa 1, Kazuyoshi Hosomichi 2, Yoshitaka Zaimoku 1, Hiroyuki Takamatsu 1, Hirohito Yamazaki 3, Ken Ishiyama 1, Rena Yamazaki 4, Hiroshi Fujiwara 4, Atsushi Tajima 2, Shinji Nakao 5　Blood Cancer J . 　13　1　165　2023/11/08
  • 　Clinical value of minimal residual disease assessment in multiple myeloma and its perspective　Hiroyuki Takamatsu　81　6　2023/06/01
  • 　Methods for the assessment of minimal residual disease in multiple myeloma　Hiroyuki Takamatsu　86　6　1　2023/06/01
  • 　Minimal Residual Disease Assessment in Myeloma:Clinical Value Using EuroFlow-Next-generation Flow　and Next-generation Sequencing　Hiroyuki Takamatsu　71　7　2023/07/01
  • 　Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs　Hiroyuki Takamatsu 1, Tomohiro Matsuda 2, Shohei Mizuno 3, Tsutomu Takahashi 4, Shin-Ichi Fuchida 5, Ichiro Hanamura 3, Keisuke Kataoka 6, Nobuhiro Tsukada 7, Morio Matsumoto 8, Akira Hangaishi 9, Noriko Doki 10, Naoyuki Uchida 11, Masashi Sawa 12, Yumiko Maruyama 13, Shingo Kurahashi 14, Koji Nagafuji 15, Yoriko Harazaki 16, Shinichi Kako 17, Shinsuke Iida 18, Tatsuo Ichinohe 19, Yoshinobu Kanda 20, Yoshiko Atsuta 21, Kazutaka Sunami 22　Haematologica 　108　12　3399　2023/12/01
  • 　Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone. 　Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kyoko Yoshihara, Satoshi Yoshihara, Mikio Ueda, Shinji Nakao, Kosei Matsue, Hiroyuki Takamatsu.　Anticancer Res. 　43　1　157　2023/01
  • 　Cardiac light-chain deposition disease and hints at diagnosing: a case report.　Nishioka R, Yoshida S, Takamatsu H, Kawano M.　Eur Heart J Case Rep.　7　2　ytad049　2023/01/30
  • 　多発性骨髄腫におけるMRD評価とその治療への応用　高松 博幸　血液内科　84　4　508　2022
  • 　多発性骨髄腫治療と微小残存病変（MRD）　田上 奈海、風間 啓敬、白井 丙午郎、高松 博幸　Therapeutic Research　43　2　115　2022
  • 　Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma?　Takamatsu H　Int J Hematol 　115　6　760　2022/06
  • 　Antibody status following booster vaccination against SARS-CoV-2 virus in patients with haematologic malignancies.　Ikeda D, Terao T, Fukumoto A, Uesugi Y, Tabata R, Kuzume A, Tsushima T, Miura D, Narita K, Takeuchi M, Yamashita T, Takamatsu H, Matsue K.　Br J Haematol.　2022/11/07
  • 　Hematopoietic stem progenitor cells with malignancy-related gene mutations in patients with acquired aplastic anemia are characterized by the increased expression of CXCR4.　Katagiri T, Espinoza JL, Uemori M, Ikeda H, Hosokawa K, Ishiyama K, Yoroidaka T, Imi T, Takamatsu H, Ozawa T, Kishi H, Yamamoto Y, Elbadry MI, Yoshida Y, Chonabayashi K, Takenaka K, Akashi K, Nannya Y, Ogawa S, Nakao S. 　EJHaem.　3　3　669　2022/06/03
  • 　Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study. 　Sunami K, Fuchida SI, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Imada K, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Onishi R, Tada K, Iida S.　Hematol Oncol.　2022/11/26
  • 　Frequent HLA-DR loss on hematopoietic stem progenitor cells in patients with cyclosporine-dependent aplastic anemia carrying HLA-DR15.　Tsuji N, Hosokawa K, Urushihara R, Tanabe M, Katagiri T, Ozawa T, Takamatsu H, Ishiyama K, Yamazaki H, Kishi H, Ogawa S, Nakao S.　Leukemia　36　6　1666　2022
  • 　A nationwide survey on central nervous system multiple myelo-ma in Japan: analysis of prognos-tic and treatment factors that impact survival　Takeshi Yamashita, Hiroyuki Takamatsu, Koji Kawamura, Kazutaka Sunami, Shotaro Hagiwara, Mitsuhiro Itagaki, Tsutomu Takahashi, Tadakazu Kondo, Ta-kashi Ikeda, Kyoko Watakabe-Inamoto, Hiroshi Handa, Yo-shitaka Imaizumi, Junya Kuroda, Jun Murakami, Yuichi Nakamura, Hideyuki Nakazawa, Shuji Ozaki, Miyuki Okura, Masami Takeuchi, Hirokazu Nagai, Ichiro Hanamura, Shinji Nakao, Shinsuke Iida　Br J Haematol　195　2　217　2021/10
  • 　Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma　① Ryota Urushihara, Naoki Takezako, Takeshi Yoroidaka, Takeshi Yamashita, Ryoichi Murata, Kenji Satou, Shinji Nakao and Hiroyuki Takamatsu.　EJHaem　4　1　184　2023/01/24
  • 　Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.　Terao T, Yamashita T, Fukumoto A, Kamura Y, Ikeda D, Kuzume A, Tabata R, Tsushima T, Miura D, Narita K, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K　Int J Hematol.　2022/02/21
  • 　Antibody response to COVID-19 vaccination in patients with lymphoma.　Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, Ikeda D, Fukumoto A, Miura D, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. 　Int J Hematol.　2022/02/21
  • 　Retrospective analysis of autolo-gous stem cell transplantation for AL amyloidosis: A Study from the Multiple Myeloma Working Group of the Japan Society for Hematopoietic Cell Transplanta-tion Transplantation and Cellular Therapy　Shin-ichi Fuchida*, Koji Kawa-mura, Kazutaka Sunami, Nobuhiro Tsukada, Shiro Fujii, Hiroshi Ohkawara, Kensuke Usuki, Atsu-shi Wake, Shinya En-do, Ken Ishiyama, Yasunori Ueda, Yuki-nori Naka-mura, Toshihiro Miyamoto, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Hi-royuki Takamatsu　Transplantation and Cel-lular Therapy　28　2　76　2022/02/28
  • 　Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents.　② Mizuno S, Takami A, Takamatsu H, Hanamura I, Shimazu Y, Hangaishi A, Tsukada N, Kako S, Kikuchi T, Ota S, Shimizu H, Iida S, Yoshioka S, Sawa M, Fukuda T, Kanda Y, Atsuta Y, Kawamura K.　Bone Marrow Transplant　2022/03/24
  • 　Effectiveness of hyperbaric oxy-gen therapy for virus-associated hemorrhagic cystitis after alloge-neic hematopoietic stem cell transplantation　Hosokawa K, Aoki G, Ohata K, Takamatsu H, Nakaga-wa N, Imi T, Iwaki N, Ito K, Kawano M, Nakamura T, Takamori M, Ishiyama K, Kondo Y, Yamazaki H, Nakao S　Int J Hematol　114　1　109　2021/07
  • 　Improved survival of multiple myeloma patients treated with autologous transplantation in the modern era of new medicine　Shimazu Y, Mizuno S, Fuchida SI, Suzuki K, Tsukada N, Hanagaishi A, Itagaki M, Kataoka K, Kako S, Sa-kaida E, Yoshioka S, Iida S, Doki N, Oyake T, Ichinohe T, Kanda Y, Astuta Y, Takamatsu H.　Cancer Sci.　112　12　5034　2021/10/13
  • 　Comparison of minimal residual disease detection in multiple myeloma between the DuraClone and EuroFlow methods　Takeshi Yoroidaka, Kentaro Narita, Hiroyuki Takamatsu, Momoko Fujisawa, Shinji Na-kao, Kosei Matsue 　Sci Rep　11　1　11218　2021/05/27
  • 　Detection of antibodies against human leukocyte antigen class II in the sera of patients receiving intravenous immunoglobulin　Hiroyuki Takamatsu, Shinya Yamada, Noriharu Nakagawa, Erika Matsuura, Atsuo Ka-sada, Keijiro Sato, Kohei Hosokawa, Noriko Iwaki, Masahisa Arahata, Hidenori Tanaka, Shinji Nakao　Transplantation Direct　7　6　e697　2021/05/18
  • 　Expression of activated integrin β7 in multiple myeloma patients　Hosen N, Yoshihara S, Takamatsu H, Ri M, Nagata Y, Kosugi H, Shimomura Y, Hanamu-ra I, Fuji S, Minauchi K, Kuroda J, Suzuki R, Nishimura N, Uoshima N, Nakamae H, Kawano Y, Mizuno I, Gomyo H, Suzuki K, Ozaki S, Nakamura S, Imai Y, Ki-zaki M, Ne-goro E, Handa H, Iida S　Int J Hematol　114　1　3　2021
  • 　Revised International Staging System allocation in the ICARIA-MM study: practical challenges and impact on outcome　Paul G. Richardson*, Aurore Per-rot, Hiroyuki Takamatsu.　eJHaem　2021
  • 　Disappearance of bulky diffuse large B-cell lymphoma after methotrexate/ infliximab with-drawal　Hiroyuki Takamatsu and Takeshi Yoroidaka.　International Journal of Hematology　115　1　1　2021/11/23
  • 　HLA class I allele-lacking leukocytes predict rare clonal evolution to MDS/AML in patients with acquired aplastic anemia. 　Kohei Hosokawa, Hiroki Mizumaki, Takeshi Yoroidaka, Hiroyuki Maruyama, Tatsuya Imi, Noriaki Tsuji, Ryota Urushibara, Mikoto Tanabe, Yoshitaka Zaimoku, Mai Anh Thi Nguyen, Dung Cao Tran, Ken Ishiyama, Hirohito Yamazaki, Takamasa Katagiri, Hiroyuki Takamatsu, Kazuyoshi Hosomichi, Atsushi Tajima, Fumihiro Azuma, Seishi Ogawa, and Shinji Nakao.　Blood　2021
  • 　Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.　Sunami K, Suzuki K, Ri M, Matsumoto M, Shimazaki C, Asaoku H, Shibayama H, Ishizawa K, Takamatsu H, Ikeda T, Maruyama D, Kaneko H, Uchiyama M, Kiguchi T, Iyama S, Murakami H, Takahashi K, Tada K, Macé S, Guillemin-Paveau H, Iida S. 　Cancer Sci.　111　12　4526　2020
  • 　Daratumumab plus bortezomib, melphalan, and prednisone in East Asian patients with non-transplant multiple myeloma: subanalysis of the randomized phase 3 ALCYONE trial.　Fujisaki T, Ishikawa T, Takamatsu H, Suzuki K, Min CK, Lee JH, Wang J, Carson R, Crist W, Qi M, Nagafuji K.　Ann Hematol.　98　12　2805　2019
  • 　Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study.　Takamatsu H (Corresponding author), Iida S, Shibayama H, Shibayama K, Yamazaki H, Suzuki K.　Int J Hematol.　111　5　692　2020
  • 　Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).　Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.　Int J Clin Oncol.　2019/04/01
  • 　Coagulation and fibrinolytic features in AL amyloidosis with abnormal bleeding and usefulness of tranexamic acid.　Arahata M, Takamatsu H, Morishita E, Kadohira Y, Yamada S, Ichinose A, Asakura H.　Int J Hematol.　111　4　550　2020
  • 　Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. 　Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K.　Ann Hematol.　99　5　1063　2020
  • 　Outcome of stem cell transplantation for Waldenström's macroglobulinemia: analysis of the Japan Society for Hematopoietic Cell Transplantation (JSHCT) Lymphoma Working Group.　Sakurai M, Mori T, Uchiyama H, Ago H, Iwato K, Eto T, Iwasaki H, Kawata T, Takamatsu H, Yamasaki S, Takanashi M, Ichinohe T, Atsuta Y, Suzuki R.　Ann Hematol. 　99　7　1635　2020
  • 　A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia. 　Mizumaki H, Hosomichi K, Hosokawa K, Yoroidaka T, Imi T, Zaimoku Y, Katagiri T, Nguyen MAT, Tran DC, Elbadry MIY, Chonabayashi K, Yoshida Y, Takamatsu H, Ozawa T, Azuma F, Kishi H, Fujii Y, Ogawa S, Tajima A, Nakao S.　Haematologica　2020
  • 　Clinical value of measurable residual disease testing for multiple myeloma and implementation in Japan.　Takamatsu H　Int J Hematol.　111　4　519　2020
  • 　Comparison between autologous and allogeneic stem cell transplantation as salvage therapy for multiple myeloma relapsing/progressing after autologous stem cell transplantation.　Ikeda T, Mori K, Kawamura K, Mori T, Hagiwara S, Ueda Y, Kahata K, Uchida N, Tsukada N, Murakami S, Yamamoto M, Takahashi T, Ichinohe T, Onizuka M, Atsuta Y, Kanda Y, Okamoto S, Sunami K, Takamatsu H.　Hematol Oncol　37　5　586　2019
  • 　Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).　Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.　Int J Clin Oncol.　24　8　966　2019
  • 　Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents. 　Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.　Bone Marrow Transplant　54　10　1595　2019
  • 　Comparison of minimal residual disease detection in multiple myeloma by SRL 8-color single-tube and EuroFlow 8-color 2-tube multiparameter flow cytometry.　Hiroyuki Takamatsu (Corresponding author), Yoroidaka T, Fujisawa M, Kobori K, Hanawa M, Yamashita T, Murata R, Ueda M, Nakao S, Matsue K.　Int J Hematol.　109　4　377　2019/04/01
  • 　Efficacy and safety of autologous stem cell transplantation in patients aged ≥ 65 years with multiple myeloma in the era of novel agents.　Mizuno S, Kawamura K, Hanamura I, Sunami K, Mori T, Nakamura F, Iida S, Nakazawa H, Makita M, Kako S, Sawa M, Ueda Y, Takahashi H, Kanda Y, Ichinohe T, Atsuta Y, Takamatsu H, Takami A.　Bone Marrow Transplant.　2019/02/19
  • 　Improved survival outcomes and relative youthfulness of multiple myeloma patients with t(4;14) receiving novel agents are associated with poorer performance of the revised international staging system in a real aging society.　Abe Y, Sunami K, Yamashita T, Ueda M, Takamatsu H, Narita K, Kobayashi H, Kitadate A, Takeuchi M, Matsue K.　Oncotarget　10　5　595　2019/01/15
  • 　Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study)　Murakami H, Kasamatsu T, Murakami J, Kiguchi T, Kanematsu T, Ogawa D, Takamatsu H, Handa H, Ozaki S, Miki H, Takahashi T, Takeo T, Yamauchi T, Morishita T, Kosugi H, Shimizu K. 　Int J Hematol.　109　4　409　2019/04/01
  • 　Clinical implications of t(11;14) in patients with multiple myeloma undergoing autologous stem cell transplantation. 　⑥ Hiroyuki Takamatsu (Corresponding author), Takeshi Yamashita, Shingo Kurahashi, Takayuki Saitoh, Tadakazu Kondo, Takeshi Maeda, Hideyuki Nakazawa, Makoto Murata, Tomoko Narita, Junya Kuroda, Hisako Hashimoto, Koji Kawamura, Toshihiro Miyamoto, Sumihisa Honda, Tatsuo Ichinohe, Yoshiko Atsuta, Kazutaka Sunami. 　Biol Blood Marrow Transplant　25　3　474　2019/03/01
  • 　RINKETSU Dictionary: Minimal residual disease in multiple myeloma　Hiroyuki Takamatsu　Rinsho Ketsueki　59　8　1118　2018/08/01
  • 　Hematopoiesis by iPSC-derived hematopoietic stem cells of aplastic anemia that escape cytotoxic T-cell attack. 　Espinoza JL, Elbadry MI, Chonabayashi K, Yoshida Y, Katagiri T, Harada K, Nakagawa N, Zaimoku Y, Imi T, Takamatsu H, Ozawa T, Maruyama H, Hassanein HA, Khalifa A Noreldin A, Takenaka K, Akashi K, Hamana H, Kishi H, Akatsuka Y, Nakao S.　Blood Adv.　2　4　390-400　2018/02/27
  • 　A comparison of minimal residual disease detection in autografts among ASO-qPCR, droplet digital PCR, and next-generation sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation.　Takamatsu H, Wee RK, Zaimoku Y, Murata R, Zheng J, Moorhead M, Carlton VEH, Kong KA, Takezako N, Ito S, Miyamoto T, Yokoyama K, Matsue K, Sato T, Kurokawa T, Yagi H, Terasaki Y, Ohata K, Matsumoto M, Yoshida T, Faham M, Nakao S.　Br J Haematol.　183　4　664－668　2018/11/01
  • 　総合内科医の臨床必須問題183問　高松 博幸　medicina　54　4　293-298　2017

Conference Presentations

  • Anti-SARS-CoV-2 antibody and T-cell responses using deep T-cell receptor immunosequencing after vaccination among healthy individuals and patients with multiple myeloma or lymphoma (conference：American Society of Hematology Annual Meeting 2022)(2022/12/12)
  • Artificial intelligence analysis of whole-body magnetic resonance imaging of patients with multiple myeloma to find prognostic factors (conference：19th International Myeloma Society Annual Meeting)(2022/08/25)
  • Prospective Comparison Study of Prognostic Value of MRD Detect-ed By 8-Color MFC (Eu-roFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting (American Society of He-matology Annual Meeting Ab-stracts #3946) (Atlanta, USA).(conference：American Society of He-matology Annual Meeting)(2021/12)
  • Comparison of MRD Detection in Autografts in Multiple Myeloma between Novel High-Sensitivity Euroflow-NGF and NGS (Ameri-can Society of Hematology An-nual Meeting Abstracts #3950) (Atlanta, USA).(conference：American Society of Hematology Annual Meeting)(2021/12)
  • Risk factors of SPMs after ASCT for MM before and after the introduction of PIs/IMiDs(2020/03)

show all

  • Minimal Residual Disease in Autografts and Bone Marrow of Patients with Multiple Myeloma: 8-Color Multiparameter Flow Cytometry (EuroFlow-NGF) vs. Next-Generation Sequencing(conference：The 62nd ASH Annual Meeting)(2020/12/06)
  • Impact of Depth of Response on Health-related Quality of Life (HRQoL) in Non-transplant NDMM(2020/10)
  • Clinical implications of t(11;14) in patients with multiple myeloma undergoing ASCT: A Nationwide Survey in Japan by JSHCT-MM-WG.(conference：第41回日本造血細胞移植学会総会)(2019/03/07)
  • Comparison of MRD detection in autografts of patients with multiple myeloma between 8-color MFC (EuroFlow-NGF) and NGS. (conference：American Society of Hematology Annual Meeting)(2018/12/01)
  • 多発性骨髄腫における微小残存病変検出の臨床的意義： 最近の話題. (conference：第43回日本骨髄腫学会学術集会、シンポジウム)(2018/05/15)
  • 多発性骨髄腫における微小残存病変検査とその臨床的意義. 第80回日本血液学会総会、教育講演。(2018/10/01)
  • Clinical implications of t(11;14) in patients with multiple myeloma who underwent autologous hematopoietic cell transplantation. The 4th World Congress on CONTROVERSIES IN MULTIPLE MYELOMA (COMy). May 3-5, 2018, Paris, France.(2017/05/03)
  • Novel human anti-HLA-Bw4 and B61 monoclonal antibodies kill malignant B cells via CDC/ADCC while sparing normal peripheral blood cells. (American Society of Hematology Annual Meeting Abstracts #2069), Blood 2017; 130: 2069 (Atlanta, USA)(2017/12/01)
  • Comparison of MRD detection in autografts of multiple myeloma patients between EuroFlow and NGS.(2017/10/01)
  • Novel human anti-HLA-Bw4 and B61 monoclonal antibodies kill malignant B cells via CDC/ADCC while sparing normal peripheral blood cells. (American Society of Hematology Annual Meeting Abstracts #2069)(2017/12/01)
  • Implementation of MRD Testing in MM in Asia(2017/11/01)
  • Development of Novel Human Anti-HLA-Monoclonal Antibodies for Clinical Applications Using Peripheral Blood B Cells Derived from Anti-HLA Antibody-Positive Donors. (American Society of Hematology Annual Meeting Abstracts #4723), Blood 2016; 128: 4723 (San Diego, USA)(2016/12/01)
  • Development of Novel Human Anti-HLA-Monoclonal Antibodies for Clinical Applications Using Peripheral Blood B Cells Derived from Anti-HLA Antibody-Positive Donors.(conference：American Society of Hematology Annual Meeting )(2016)
  • Development of novel human anti-HLA monoclonal antibodies　for clinical applications using blood derived from anti-HLA　antibody positive donors(conference：The 29th Annual and International Meeting of the Japanese Association of Animal Cell Technonology)(2016/11)
  • COMPARISON BETWEEN 8-COLOR MULTIPARAMETER FLOW CYTOMETRY AND NEXT-GENERATION SEQUENCING TO DETECT MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA PATIENTS WHOUNDERWENT AUTO-SCT(conference：21th congress of the European Hematology Association Meeting)(2016/06)
  • Prognostic Value of Sequencing-Based Minimal　Residual Disease Detection　in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell　Transplantation. (conference：American Society of Hematology Annual Meeting)(2015/12)
  • A Comparison of Minimal Residual Disease Detection Among ASO-PCR, Dd-PCR and Deep-Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation(conference：American Society of Hematology Annual Meeting)(2015/12)
  • Comparison of minimal residual disease detection in multiple myeloma between multiparameter flow cytometry and deep-sequencing(conference：15th International Myeloma Workshop)(2015/09)
  • Prognostic value of minimal residual disease response assessment in multiple myeloma(2015/07)
  • Prognostic Value of Sequencing-Based Minimal Residual Disease Detection in Multiple Myeloma(conference：American Society of Hematology Annual Meeting)(2014/12)
  • A COMPARISON BETWEEN NEXT-GENERATION SEQUENCING AND ASO-QPCR FOR MINIMAL RESIDUAL　DISEASE DETECTION IN MULTIPLE MYELOMA: THE CLINICAL VALUE IN ASCT SETTING(conference：19th congress of the European Hematology Association Meeting)(2014)
  • A Comparison Between Next-Generation Sequencing and ASO-qPCR For Minimal Residual Disease Detection In Multiple Myeloma(conference：American Society of Hematology Annual Meeting)(2013/12)
  • Significance of the ISS and IMWG response criteria in patients with multiple myeloma who received ASCT in the novel agent era: a retrospective analysis of 1701 Japanese patients(conference：18th congress of the European Hematology Association Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma(conference：18th congress of the European Hematology Association Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for minimal residual disease detection in multiple myeloma(conference：American Society of Clinical Oncology Annual Meeting)(2013)
  • A comparison between next-generation sequencing and ASO-qPCR for MRD detection in multiple myeloma(conference：14th International Myeloma Workshop)(2013/04)
  • Detection of Minimal Residual Disease in Patients with Multiple Myeloma by PCR-Based IGH Gene Clonality Analysis Using DNA Extracted From Archival Bone Marrow Slides(conference：American Society of Hematology Annual Meeting)(2011/12)
  • Role of Moesin in Murine Hematopoiesis(conference：American Society of Hematology Annual Meeting)(2011/12)
  • Identification of a Novel Auto-Antibody Highly Prevalent in Patients with Hepatitis-Associated and Idiopathic Aplastic Anemia(conference：American Society of Hematology Annual Meeting)(2009/12)
  • Roles of autoantibodies in the pathophysiology of bone marrow failure syndromes(conference：The 4th Asian Hematology Seminar)(2009/02/20)
  • Specific Antibodies to Moesin, a Membrane-Cytoskeleton Linker Protein, Are Frequently Detected in Patients with Immune-Mediated Aplastic Anemia(conference：American Society of Hematology Annual Meeting)(2005/12)
  • Stimulation of TNF- Production from Monocytes by Anti-Moesin Antibodies in the Serum of Patients with Aplastic Anemia: A Novel Mechanism of Myelosuppression by Autoantibodies(conference：American Society of Hematology Annual Meeting)(2006/12)
  • Study of hybridoma cells' kinetics in high-density culture(conference：Asian-Pacific Biochemical Engineering Conference)(1992)
  • Prognostic value of sequencing-based minimal residual disease detection in multiple myeloma.(conference：The 76th Annual Meeting of the Japanese Society of Hematology)(2014/10)

Others

Arts and Fieldwork

Patent

Theme to the desired joint research

Grant-in-Aid for Scientific Research

○「サイトカイン産生を誘導する自己抗体を用いた骨髄不全モデルマウスの作成 」(2009-2011)　
○「自己抗体とCLIP置換型Ii鎖ライブラリーを利用した再生不良性貧血自己抗原の同定 」(2007-)　
○「自己抗体による免疫担当細胞からのサイトカイン分泌増強を介した骨髄不全病態の解析 」(2007-)　
○「再生不良性貧血における免疫抑制療法の効果予測法の確立 」(2006-)　
○「患者B細胞を用いたモノクローナル抗体作製とその臨床応用」(2018-2020)　
○「次世代シークエンサーと蛋白質アレイを用いた骨髄腫病態解析と新規治療法の開発」(2015-2017)　

Competitive research funding,Contribution

Collaborative research,Consignment study

Classes (Bachelors)

Classes (Graduate Schools)

○The Human Body in Health and Disease Curriculum 4(2019)
○Introduction to Molecular Biology of Cancer(2019)
○Itemized Lectures on Clinical Oncology(2019)
○Overview of Cellular Transplantation Biology(2019)
○The Human Body in Health and Disease Curriculum 4(2018)
○Itemized Lectures on Clinical Oncology(2018)
○Overview of Cellular Transplantation Biology(2018)
○Introduction to Molecular Biology of Cancer(2018)
○Introduction to Molecular Biology of Cancer(2017)
○Itemized Lectures on Clinical Oncology(2017)
○Introduction to Molecular Biology of Cancer(2017)
○Itemized Lectures on Clinical Oncology(2017)
○Overview of Cellular Transplantation Biology(2017)
○Overview of Cellular Transplantation Biology(2017)
○Itemized Lectures on Clinical Oncology(2016)
○Overview of Cellular Transplantation Biology(2016)
○Itemized Lectures on Clinical Oncology(2016)
○Introduction to Molecular Biology of Cancer(2016)
○Overview of Cellular Transplantation Biology(2016)
○Introduction to Molecular Biology of Cancer(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top